III. Medizinische Klinik (Hämatologie und Onkologie)




Arbeitsgruppe Max Eder-Research Group

„ Mechanisms of Tumor Cell Survival“


Principal Investigator:
PD Dr. Philipp J. Jost
III. Medizinische Klinik und Poliklinik
Klinikum rechts der Isar
Technische Universitaet Muenchen
Tel: (089) 4140-5941
Fax: (089) 4140-4879

e-Mail: philipp.jost(a)tum.de


Lab Members

  • Dr. Monica Yabal, (Ph.D., University of Helsinki) Postdoc
  • Ulrike Höckendorf, (Dipl. hum. biol. Uni Greifswald), Postdoc
  • Dr. Stefanie Jilg (TUM), Resident
  • Nicole Müller (BSc Uni Salzburg, MSc Uni Erlangen) Ph.D. Student
  • Enkhtsetseg (Jiji) Munkhbaatar (MD, Medical School Ulaan Bator, MSc Uppsala) Ph.D. Student
  • Wang Xin (MSc,Nanjing, China), PhD
  • Deepti Singh (MSc. University of Delhi, India), PhD Student
  • Stephanie Rott (B.Sc, Uni Magdeburg), Research Assistant
  • Anne Jacob (Dipl. Biol., Universität Ulm), Research Assistant
  • Veronika Reidel (cand. med. TU München), medizinische Doktorandin
  • Adam Wahida (cand. med. RWTH Aachen)
  • Johanna Kauschinger (cand. med. TU München), medizinische Doktorandin
  • Anna-Lena Meinhardt (cand. med. TU München), medizinische Doktorandin
  • Richard Hauch (can. med. TU München), Medizinischer Doktorand

Current Research Interests

Our research group studies the regulation of apoptosis in healthy and malignant cells. The focus of our work is the understanding of cell death mechanisms and their regulation in tumor cell initiation, tumor maintenance and resistance mechanisms. As model systems we employ genetic deletion or pharmacologic inhibition of individual pro- and anti-apoptotic proteins in various murine tumor models. In addition we also employ spatiotemporal deletion of individual anti-apoptotic proteins for characterization of their role in tumor initiation and maintenance as well as characterization of the function of anti-apoptotic regulators in development and sustained growth of human lymphoma and leukaemia.


Applications

Written applications including CV and the names of 2 professional referees are welcome and should be forwarded by email to Dr. Philipp Jost.

Fellowship options:

Funding

Else Kröner Fresenius Stiftung
Deutsche Forschungsgemeinschaft Forschergruppe FOR2036
Deutsche Krebshilfe (Max Eder-Programm)
Human Frontiers Science Program (HFSP)
Deutsche Jose Carreras Leukämiestiftung DJCLS R 12/22

Selected Publications

Höckendorf U*, Yabal M*, Herold T, Munkhbaatar E, Rott S, Jilg S, Kauschinger J, Magnani G, Reisinger F, Heuser M, Kreipe H, Sotlar K, Engleitner T, Rad R, Weichert W, Peschel C, Ruland J, Heikenwalder H, Spiekermann K, Slotta-Huspenina J, Groß O, and Jost PJ.
RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells.
Cancer Cell, 2016, 30, 75-91.

Spinner S, Crispatzu G, Yi JH, Munkhbaatar E, Mayer P, Höckendorf U, Müller N, Li Z, Schader T, Bendz H, Hartmann S, Yabal M, Pechloff K, Heikenwalder M, Kelly GL, Strasser A, Peschel C, Hansmann ML, Ruland J, Keller U, Newrzela S, Herling M, Jost PJ.
Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.
Leukemia. 2016, 30, 1520-30.

Jilg S, Reidel V, Müller-Thomas C, König J, Schauwecker J, Höckendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, Ruland J, Kolb HJ, Peschel C, Oostendorp RA, Götze KS, Jost PJ.
Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.
Leukemia. 2016, 30, 112-123.

Yabal M, Müller N, Adler H, Knies N, Groß CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwälder M, Strasser A, Groß O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ.
XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation.
Cell Rep. 2014, 7, 796-808.

Damgaard RB*, Nachbur U*, Yabal M*, Wong WWL, Fiil BK, Kastirr M, Rieser E, Rickard JA, Bankovacki A, Peschel C, Ruland J, Bekker-Jensen S, Mailand N, Kaufmann T, Strasser A, Walczak H, Silke J, Jost PJ*#, Gyrd-Hansen M*# (*: equal contribution; #: corresponding author).
The ubiquitin ligase XIAP  recruits LUBAC for NOD2 signaling in inflammation and innate immunity.
Molecular Cell, 2012, doi:10.1016/j.molcel.2012.04.014, epub online.

Kaufmann, T., Strasser, A., Jost PJ. Fas Death Receptor Signalling: Roles of Bid and XIAP. Cell Death and Differentiation 2012,19,42-50

Vikstrom I., Carotta S., Lüthje K., Peperzak V., Jost PJ., Glaser S., Busslinger M., Bouillet P., Strasser A., Nutt SL., Tarlinton DM., Mcl-1 is Essential for Germinal Center Formation and B cell Memory,
Science 2010, 330, 1095-9

Jost, PJ., Grabow, S., Gray, D., McKenzie, MD., Nachbur, U., Huang, DCS., Bouillet, P., Thomas, HE., Borner, C., Silke, J., Strasser, A., Kaufmann, T. XIAP discriminates between type I and type II FAS-induced apoptosis.
Nature
, 2009, 460, 1035-9.



PD Dr. Philipp J. Jost



2010 · III. Medizinische Klinik (Hämatologie / Onkologie) am Klinikum rechts der Isar der Technischen Universität München